Elvitegravir (Molecule of the Month for May 2017)
Vitekta
Elvitegravir is an integrase inhibitor used to treat HIV infection. According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.
Elvitegravir inhibits the enzyme integrase of HIV-1, and of HIV-2 to a lesser extent. The virus needs this enzyme to integrate its genetic code into the host's DNA.
Formal Chemical Name (IUPAC)
(S)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
References
click on the picture of Elvitegravir above to interact
with the 3D model of the
Elvitegravir structure
(this will open a new browser window)
C23H23ClFNO5
Update by Karl Harrison
(Molecule of the Month for
May 2017
)
All the images on this web site are are made available with a Creative Commons Attribution license and so can be used as long as the attribution © Karl Harrison 3DChem.com is written with the image. High resolution images and illustrations are available on request.